Immune cells can eliminate cancer cells by releasing cytotoxic vesicles or via the action of the death ligands CD95/Fas or CD253/TRAIL. TRAIL can induce programmed cell death after binding to its death receptors (DR)4 and DR5. This pathway has high therapeutic appeal due to TRAIL’s selective cytotoxicity towards malignant, but not healthy, cells. However, tumour cells can escape this immune surveillance by switching the signalling downstream of DRs from the pro-apoptotic (canonical) signal towards a survival (non-canonical) signal. The main goal of the MSCA-SE project CHIRON is to sufficiently advance our mechanistic understanding of the non-canonical DR-signalling pathway and its related cellular processes in tumour and immune cells to be able to successfully alter it for therapeutic purposes.
This project received funding from the European Union, through its research and innovation programme - Horizon Europe, under grant agreement No 101130240 (CORDIS page).
Find out more about the project on its website: CHIRON website
Linkedin: www.linkedin.com/showcase/trail4life
X/Twitter: @Trail4Life-eu